Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -9.45
- Piotroski Score 2.00
- Grade Buy
- Symbol (CRDL)
- Company Cardiol Therapeutics Inc.
- Price $1.56
- Changes Percentage (-5.78%)
- Change -$0.1
- Day Low $1.54
- Day High $1.64
- Year High $3.12
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $8.00
- High Stock Price Target $8.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.34
- Trailing P/E Ratio -7.09
- Forward P/E Ratio -7.09
- P/E Growth -7.09
- Net Income $-28,128,291
Income Statement
Quarterly
Annual
Latest News of CRDL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate
Investors are attracted to unprofitable companies like Cardiol Therapeutics due to high share price growth, despite cash burn risks. With a cash runway of 15 months, the company aims for cash flow bre...
By Yahoo! Finance | 4 months ago
